Trials / Recruiting
RecruitingNCT06447597
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Study to Evaluate the Efficacy and Safety of B007 in Subjects With Generalized Myasthenia Gravis
- Status
- Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 104 (estimated)
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with generalized myasthenia gravis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | B007 | B007 high dose and low dose： Subcutaneous injection was administered on days 1 and 15 |
| DRUG | Placebo | B007 matched Placebo Subcutaneous injection was administered on days 1 and 15 |
Timeline
- Start date
- 2024-07-01
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
- First posted
- 2024-06-07
- Last updated
- 2024-10-31
Locations
18 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06447597. Inclusion in this directory is not an endorsement.